Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX)
2.5900
+0.0500 (1.97%)
NYSE · Last Trade: Apr 2nd, 6:34 PM EDT
A fundamental and technical analysis of (NYSEARCA:PLX): Is PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) suited for high growth investing?
Via Chartmill · March 22, 2025
Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.
Via Benzinga · March 17, 2025

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via Benzinga · November 6, 2023

PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 14, 2024

PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 10, 2024

Notable NFT news this week is from video game retailer GameStop, which has announced its NFT marketplace will shut down next month. The publicly-traded company is citing “regulatory uncertainty” for its decision to discontinue the NFT business.
Via Talk Markets · January 14, 2024

Via Benzinga · May 4, 2023
Looking Into Protalix BioTherapeutics's Return On Capital Employedbenzinga.com
Via Benzinga · December 23, 2022

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
Via Benzinga · March 14, 2024

The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · October 23, 2023

Via Benzinga · August 7, 2023

The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult
Via Benzinga · May 10, 2023

It's time for another dive into the biggest pre-market stock movers as we see what shares are on rising and falling on Tuesday!
Via InvestorPlace · May 10, 2023

Gainers Lucira Health, Inc. (NASDAQ: LHDX) rose 228.5% to $0.46 in pre-market trading after the FDA authorized Lucira's over-the-counter at-home test to detect both influenza and COVID-19 viruses.
Via Benzinga · February 27, 2023

The Dow Jones closed lower by more than 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · January 6, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
Via Benzinga · February 27, 2023